Discussing the potential of Takeda's Dengue Vaccine candidate, QDENGA, and Valneva SE's single-shot Chikungunya Vaccine candidate, VLA1553

Executed on:Dec 21, 2022 2:45 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Weill Cornell MedicineAssociate Professor of Medicine at Weill Cornell & Associate Attending Physician at New York- Presbyterian Hospital.
Research focused on influenza virus pathogenesis and therapy in the immunocompromised human host.
Member of the International Society for Travel Medicine (ISTM) and she a fellow of the Infectious Diseases Society of America (IDSA).

Interview Goal

We will be discussing the potential of Valneva's single-shot chikungunya vaccine candidate, VLA1553 and the results from the Phase 3 VLA1553-301 trial of VLA1553 in adults. We will also be diving into the potential of QDENGA(TAK-003), a dengue vaccine candidate, which was granted priority review by the FDA for it's BLA.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.